Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection
作者： Robert L. Murphy , Roy M. Gulick , Victor DeGruttola , Richard T. D'Aquila , Joseph J. Eron
DOI: 10.1086/314668
关键词:
摘要: Amprenavir is a human immunodeficiency virus (HIV) protease inhibitor with favorable pharmacokinetic profile and good in vitro activity. Ninety-two lamivudine- inhibitor-naive individuals ≥50 CD4 cells/mm 3 ≥5000 HIV RNA copies/mL were assigned amprenavir (1200 mg) alone or zidovudine (300 plus lamivudine (150 mg), all given every 12 h. After median follow-up of 88 days, the findings planned interim review resulted termination monotherapy arm. Among 85 subjects confirmed plasma determination, 15 42 versus 1 43 tripletherapy had an increase above baseline log 10 nadir (P = .0001). For taking triple therapy at 24 weeks, decrease was 2.04 copies/mL, 17 (63%) 27 evaluable <500 copies/mL. Treatment amprenavir, zidovudine, together reduced levels significantly more than did monotherapy.
oup.com
paperity.org
oxfordjournals.org
jstor.org 参考文章(25)
Xiping Wei, Sajal K. Ghosh, Maria E. Taylor, Victoria A. Johnson, Emilio A. Emini, Paul Deutsch, Jeffrey D. Lifson, Sebastian Bonhoeffer, Martin A. Nowak, Beatrice H. Hahn, Michael S. Saag, George M. Shaw, Viral dynamics in human immunodeficiency virus type 1 infection Nature. ,vol. 373, pp. 117- 122 ,(1995) , 10.1038/373117A0
N. E. Kohl, E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, I. S. Sigal, Active human immunodeficiency virus protease is required for viral infectivity. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 85, pp. 4686- 4690 ,(1988) , 10.1073/PNAS.85.13.4686
Yves Mouton, Serge Alfandari, Michel Valette, François Cartier, Pierre Dellamonica, Guy Humbert, Jean Marie Lang, Patrice Massip, Denis Mechali, Pascale Leclercq, Jacques Modai, Henri Portier, Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA. AIDS. ,vol. 11, ,(1997) , 10.1097/00002030-199712000-00003
M.H. St. Clair, J. Millard, J. Rooney, M. Tisdale, N. Parry, B.M. Sadler, M.R. Blum, G. Painter, In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents Antiviral Research. ,vol. 29, pp. 53- 56 ,(1996) , 10.1016/0166-3542(95)00916-7
Jon H. Condra, William A. Schleif, Olga M. Blahy, Lori J. Gabryelski, Donald J. Graham, Julio Quintero, Audrey Rhodes, Helen L. Robbins, Elizabeth Roth, Malathi Shivaprakash, Donna Titus, Tao Yang, Hedy Tepplert, Kathleen E. Squires, Paul J. Deutsch, Emilio A. Emini, In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature. ,vol. 374, pp. 569- 571 ,(1995) , 10.1038/374569A0
E. E. Kim, C. T. Baker, M. D. Dwyer, M. A. Murcko, B. G. Rao, R. D. Tung, M. A. Navia, Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme Journal of the American Chemical Society. ,vol. 117, pp. 1181- 1182 ,(1995) , 10.1021/JA00108A056
B. G. Rao, E. E. Kim, M. A. Murcko, Calculation of solvation and binding free energy differences between VX-478 and its analogs by free energy perturbation and AMSOL methods Journal of Computer-aided Molecular Design. ,vol. 10, pp. 23- 30 ,(1996) , 10.1007/BF00124462
David D. Ho, Avidan U. Neumann, Alan S. Perelson, Wen Chen, John M. Leonard, Martin Markowitz, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature. ,vol. 373, pp. 123- 126 ,(1995) , 10.1038/373123A0
Manuel A Navia, Mark A Murcko, Use of structural information in drug design Current Biology. ,vol. 2, pp. 172- ,(1992) , 10.1016/0960-9822(92)90500-A
A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho, HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time Science. ,vol. 271, pp. 1582- 1586 ,(1996) , 10.1126/SCIENCE.271.5255.1582